HUTCHMED
- FLASCO
- April 8, 2022
- No Comments
HUTCHMED is an innovative, global, biopharmaceutical company committed to the discovery and development of targeted oncology therapies, inclusive of neuroendocrine tumors.
HUTCHMED is an innovative, global, biopharmaceutical company committed to the discovery and development of targeted oncology therapies, inclusive of neuroendocrine tumors.
We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, who have expanded…
About Blueprint Medicines Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and…
Epizyme’s vision is to rewrite treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme aspires to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. Learn more Epizyme.com. Patient Assistance & Product Support: EpizymeNOW 1-833-4EPI(NOW) (437-4669)
COMPANY OVERVIEW Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. In December…
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and others. Rigel’s first FDA approved product…
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical…
The importance of ONE package. As part of AmerisourceBergen Oncology Supply meticulously distributes chemotherapy, immunotherapy and supportive care products to community oncology practices nationwide from our office and distribution center in Dothan, Alabama. As your trusted supplier and solutions partner, we go beyond the product, delivering the key knowledge that creates opportunities for growth, solutions…
Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Our…
© 2021 FLASCO | Premium Website Design by The HDG